Market Overview:
The global CAR T-cell therapy market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, technological advancements in CAR T-cell therapy, and rising funding for CAR T-cell therapy research. However, the high cost of treatment and lack of reimbursement policies are restraining the growth of this market. The global CAR T-cell therapy market can be segmented on the basis of type into allogeneic and autologous therapies. Allogeneic therapies are those that use cells from a donor other than the patient receiving treatment. Autologous therapies use cells from the patient receiving treatment. On the basis of application, this market can be segmented into hospitals, cancer research centers, and others (including clinics and academic institutions). Geographically, this market can be segmented into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa . North America is expected to dominate this market duringthe forecast period owingto early adoptionof new technologiesand strong presenceof key playersinthis region .
Product Definition:
CAR T-cell therapy is a cellular immunotherapy treatment that uses genetically modified T cells from a patient to fight cancer. The cells are modified in the lab to express a chimeric antigen receptor (CAR), which is designed to target and kill specific cancer cells. CAR T-cell therapy is important because it can specifically target tumor cells, unlike traditional chemotherapy or radiation treatments, which can cause widespread damage to healthy tissues.
Allogeneic:
Allogeneic cells are those obtained from another individual. They are often used in transplantation procedures and referred to as the white blood cells (WCB). The allogeneic WCB is a source of T-cell receptor signaling for initiating immune response against the foreign body. In CAR T-Cell Therapy, these WCB's are extracted from donor individuals and then modified to become an effective therapy for treating cancerous tumors by changing their gene expression.
Autologous:
Autologous cellular therapy is a type of cell-based therapy that involves the infusion of T cells from a patient's immune system that are directed against cancer. These cells are extracted and then put back into the patient's body where they attack cancer cells. This process is known as autologous cellular transplantation or allogeneic bone marrow transplant (BMT). Autologous BMT has been used for more than 50 years to treat leukemia and lymphoma, most notably in children.
Application Insights:
The others segment held the largest share of 66.0% in 2017 owing to the growing number of autologous and allogeneic stem cell therapies for non-malignant diseases. Non-malignant diseases include diabetes, Parkinson¢â‚¬â„¢s disease, multiple sclerosis, and rheumatoid arthritis. The increasing prevalence of these disorders is expected to boost demand over the forecast period.
Cancer research centers accounted for a significant share in 2017 due to increasing government funding for cancer research coupled with rising incidence rates of various types of cancers across the globe. According to WHO data published in 2018, an estimated 9 million new cases were registered globally that year along with around 4 million deaths caused by cancer worldwide which represented a 2% increase compared with 2015 estimates.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, advanced healthcare infrastructure and high adoption rate of novel therapies. The U.S holds a major share in this region due to its well-developed economy and strong research base for CAR T-cell therapy development.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising investments by governments as well as private organizations for improving healthcare facilities across countries such as China, India and Japan (CIJ).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the CAR T-cell therapy market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for CAR T-cell therapies over the forecast period.
- Rising awareness about CAR T-cell therapy: There is a rising awareness about CAR T-cell therapy among patients and healthcare professionals due to its promising clinical results in treating various types of cancers such as leukemia, lymphoma, and solid tumors. This is expected to boost adoption rates for these therapies over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
CAR T-Cell Therapy Market Research Report
By Type
Allogeneic, Autologous
By Application
Hospitals, Cancer Research Centers, Others
By Companies
Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics, Mustang Bio, Bluebird Bio, Collectis, Allogene Therapeutics, Celyad
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global CAR T-Cell Therapy Market Report Segments:
The global CAR T-Cell Therapy market is segmented on the basis of:
Types
Allogeneic, Autologous
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Cancer Research Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene (Juno Therapeutics)
- Novartis
- Gilead (Kite Pharma)
- Pfizer
- CARsgen Therapeutics
- Autolus Therapeutics
- Aurora BioPharma
- Sorrento Therapeutics
- Mustang Bio
- Bluebird Bio
- Collectis
- Allogene Therapeutics
- Celyad
Highlights of The CAR T-Cell Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Allogeneic
- Autologous
- By Application:
- Hospitals
- Cancer Research Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CAR T-Cell Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CAR T-Cell Therapy is a treatment for cancer that uses genetically modified T cells to kill the cancer.
Some of the key players operating in the car t-cell therapy market are Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics, Mustang Bio, Bluebird Bio, Collectis, Allogene Therapeutics, Celyad.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CAR T-Cell Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 CAR T-Cell Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 CAR T-Cell Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the CAR T-Cell Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global CAR T-Cell Therapy Market Size & Forecast, 2018-2028
4.5.1 CAR T-Cell Therapy Market Size and Y-o-Y Growth
4.5.2 CAR T-Cell Therapy Market Absolute $ Opportunity
Chapter 5 Global CAR T-Cell Therapy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 CAR T-Cell Therapy Market Size Forecast by Type
5.2.1 Allogeneic
5.2.2 Autologous
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global CAR T-Cell Therapy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 CAR T-Cell Therapy Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Cancer Research Centers
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global CAR T-Cell Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 CAR T-Cell Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America CAR T-Cell Therapy Analysis and Forecast
9.1 Introduction
9.2 North America CAR T-Cell Therapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America CAR T-Cell Therapy Market Size Forecast by Type
9.6.1 Allogeneic
9.6.2 Autologous
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America CAR T-Cell Therapy Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Cancer Research Centers
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe CAR T-Cell Therapy Analysis and Forecast
10.1 Introduction
10.2 Europe CAR T-Cell Therapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe CAR T-Cell Therapy Market Size Forecast by Type
10.6.1 Allogeneic
10.6.2 Autologous
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe CAR T-Cell Therapy Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Cancer Research Centers
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific CAR T-Cell Therapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific CAR T-Cell Therapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific CAR T-Cell Therapy Market Size Forecast by Type
11.6.1 Allogeneic
11.6.2 Autologous
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific CAR T-Cell Therapy Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Cancer Research Centers
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America CAR T-Cell Therapy Analysis and Forecast
12.1 Introduction
12.2 Latin America CAR T-Cell Therapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America CAR T-Cell Therapy Market Size Forecast by Type
12.6.1 Allogeneic
12.6.2 Autologous
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America CAR T-Cell Therapy Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Cancer Research Centers
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) CAR T-Cell Therapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) CAR T-Cell Therapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) CAR T-Cell Therapy Market Size Forecast by Type
13.6.1 Allogeneic
13.6.2 Autologous
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) CAR T-Cell Therapy Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Cancer Research Centers
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 CAR T-Cell Therapy Market: Competitive Dashboard
14.2 Global CAR T-Cell Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Celgene (Juno Therapeutics)
14.3.2 Novartis
14.3.3 Gilead (Kite Pharma)
14.3.4 Pfizer
14.3.5 CARsgen Therapeutics
14.3.6 Autolus Therapeutics
14.3.7 Aurora BioPharma
14.3.8 Sorrento Therapeutics
14.3.9 Mustang Bio
14.3.10 Bluebird Bio
14.3.11 Collectis
14.3.12 Allogene Therapeutics
14.3.13 Celyad
